Results 161 to 170 of about 4,882 (214)

Pharmacokinetic evaluation of idebenone

Expert Opinion on Drug Metabolism and Toxicology, 2010
Idebenone is a synthetic short chain benzoquinone that acts as an electron carrier in the mitochondrial electron transport chain, thereby, facilitating the production of ATP. In addition, idebenone is an antioxidant and can inhibit lipid peroxidation and may protect cell membranes and mitochondria from oxidative damage.
Claudia Becker
exaly   +3 more sources

Efficacy of idebenone in Duchenne muscular dystrophy

Lancet, The, 2015
no abstract ...
Eugenio Mercuri, Francesco Muntoni
exaly   +3 more sources

Idebenone: An emerging therapy for Friedreich ataxia

Journal of Neurology, 2009
This paper reviews the history and pre-clinical development of idebenone and summarises the results of clinical studies, published from 1999 to 2008, on the use of idebenone in the treatment of patients with Friedreich ataxia (FRDA). As a benzoquinone that can undergo reversible redox reactions, idebenone influences the electron balance in mitochondria.
Thomas, Meier, Gunnar, Buyse
exaly   +3 more sources

Idebenone: A Review in Leber’s Hereditary Optic Neuropathy

Drugs, 2016
Idebenone (Raxone(®)), a short-chain benzoquinone, is the only disease-specific drug approved to treat visual impairment in adolescents and adults with Leber's hereditary optic neuropathy (LHON), a rare genetic mitochondrial disease that causes rapid and progressive bilateral vision loss.
Katherine A Lyseng-Williamson
exaly   +3 more sources

Idebenone in Friedreich's ataxia

Expert Opinion on Pharmacotherapy, 2008
Friedreich's ataxia is an autosomal recessive neurodegenerative disease where impaired mitochondrial function and excessive production of free radicals play a central pathogenetic role. Idebenone, a synthetic analogue of coenzyme Q, is a powerful antioxidant that was first administrated to Friedreich's ataxia patients less than 10 years ago.The aim of ...
TONON, CATERINA, LODI, RAFFAELE
openaire   +2 more sources

Idebenone in patients with Friedreich ataxia

Neuroscience Letters, 2001
Friedreich ataxia (FA), the most common form of degenerative ataxia, is thought to be caused by respiratory deficiency due to mitochondrial iron accumulation and oxidative stress. Idebenone, a free-radical scavenger, protects mitochondrial function in in vitro models of FA.
Schöls, L., Vorgerd, M., Schillings, M., Skipa, G., Zange, J.   +4 more
openaire   +3 more sources

Pharmacokinetic properties and metabolism of idebenone

Journal of Neurology, 2009
Four phase 1 studies were conducted to assess the pharmacokinetics and metabolism of idebenone (including parent drug and inactive metabolites QS10, QS6, and QS4) and to evaluate the safety of a wide range of idebenone doses and regimens in healthy adult men.
Kutz, Klaus, Drewe, Jürgen, Vankan, Pierre   +2 more
openaire   +2 more sources

Idebenone for treatment of Friedreich’s ataxia?

Neurology, 2003
The treatment of the hereditary ataxias remains challenging and difficult. Harding, in her book, The Hereditary Ataxias and Spastic Paraplegias ,1 quotes Whyte (1898): “Almost all writers on this part of the subject speak in most hopeless tone”; and she comments that very little has changed since then.
FILLA, ALESSANDRO, Moss, Arthur J.
openaire   +2 more sources

Investigating idebenone and idebenone linoleate metabolism: in vitro pig ear and mouse melanocyte studies

Journal of Cosmetic Dermatology, 2009
SummaryObjective  The aim of this study was to investigate inherent in vitro permeability, metabolism, and cytotoxicity of idebenone – an active used to protect skin as an anti‐aging agent – and compare it to idebenone linoleate.Methods  Idebenone and idebenone linoleate were investigated in pig ear skin and melanoma (B16: F10 mouse) cells.
Wempe, Michael F., Lightner, Janet W., Zoeller, Elizabeth L., Rice, Peter J.   +3 more
openaire   +3 more sources